51. Lipopolysaccharide-dependent transcriptional regulation of PU.1 in microglial cells
- Author
-
Ji Yoon Park, Young Gyu Chai, Taeho Yoon, Chanchal Mandal, and Kyoung Hwa Jung
- Subjects
0301 basic medicine ,Chemokine ,biology ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Promoter ,Toxicology ,Pathology and Forensic Medicine ,Cell biology ,ChIP-sequencing ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Gene expression ,biology.protein ,Transcriptional regulation ,General Pharmacology, Toxicology and Pharmaceutics ,Enhancer ,Gene ,Transcription factor - Abstract
PU.1 is a pioneer transcription factor and a master regulator of the myeloid lineage. However, the role of PU.1 in lipopolysaccharide-dependent microglial activation has yet to be investigated. So, this study was conducted to determine the effects of PU.1 in LPS-induced activation of microglial cells. We knocked out PU.1 in murine BV-2 cells using the CRISPR-Cas9 system to investigate the role of PU.1 in the expression of immune-related genes. We performed RNA sequencing (RNA-seq) of PU.1 KO and BV-2 cells to analyze the gene expression patterns in PU.1 KO cells and compare them to those in wild-type BV-2 cells. The validation of differential expressions was achieved by qRT-PCR. To explore this regulatory role of PU.1, ChIP sequencing for PU.1 and H3K27Ac was performed. The sequencing result was further confirmed by ChIP-qPCR. RNA sequencing and subsequent bioinformatic analysis revealed that the expression of most of the immune-related genes was suppressed in the absence of PU.1. Proinflammatory chemokine genes were differentially expressed in LPS-treated PU.1 KO cells. The ChIP sequencing result followed by ChIP-qPCR revealed a LPS-mediated increase in the enrichment of PU.1 binding in pro-inflammatory chemokine gene promoters and enhancer regions in wild-type BV-2 cells. There was no enrichment of PU.1 in PU.1 KO cells. The above-mentioned results suggest that PU.1 is directly involved in regulating the immune response and that this regulation of inflammatory chemokines is LPS-dependent. We hope that PU.1 would be an option for limiting neurodegeneration in a diverse range of neurological disorders.
- Published
- 2019
- Full Text
- View/download PDF